Applied Molecular Evolution (AME) is a leader in applying directed molecular evolution to improve healthcare by discovering, optimizing and developing human biotherapeutics. Since its inception, AME’s principal focus has been on applying its proprietary AMEsystem™ technology platform to the full range of protein therapeutic candidates including antibodies, cytokines, hormones and enzymes to develop novel human biotherapeutic candidates.
Since February 2004, AME has been a wholly-owned subsidiary of Eli Lilly and Company and is an integral part of Lilly’s research organization. Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.
While geographically separate, AME works closely with Lilly colleagues in Indianapolis and around the world, sharing a corporate legacy of integrity and commitment to quality that spans more than a century.